CAS NO: | 155488-25-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally activeGastrin/CCK-Bantagonist with anIC50value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with anIC50of 502 nM[1]. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, withKivalues of 0.068, 0.62 and 0.19 nM, respectively[2]. | ||||||||||||||||
IC50& Target | IC50: 0.1 nM (Gastrin/CCK-B); 501 nM (Gastrin/CCK-A)[1] | ||||||||||||||||
体内研究 (In Vivo) | Sograzepide (Netazepide; YF 476; YM-220) (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anethsetized rats with an ED50of 87 nmol/kg[1].Sograzepide (Netazepide; YF 476; YM-220) (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion with an ED50value of 0.0086 μM/kg, but does not affect histamine- and bethanechol-induced acid secretion[2].Sograzepide (Netazepide; YF 476; YM-220) (intravenous injection; oral administration) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner with ED50values of 0.018 and 0.020 μM/kg, respectively[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 498.58 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C28H30N6O3 | ||||||||||||||||
CAS 号 | 155488-25-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(200.57 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|